Dan Veljovich, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    GSK
    Topic:
    Parp inhibitor consulting and speaker's bureau
    Date added:
    08/24/2022
    Date updated:
    04/25/2024
    Relationship end date:
    08/24/2022
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    AstraZeneca
    Topic:
    Parp inhibitor consulting and speaker's bureau
    Date added:
    08/24/2022
    Date updated:
    04/25/2024
    Relationship end date:
    08/24/2022
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Eisai
    Topic:
    Immunotherapy and TKI for uterine cancer
    Date added:
    08/24/2022
    Date updated:
    04/25/2024
    Relationship end date:
    08/24/2022
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Merck
    Topic:
    Immunotherapy and TKI for uterine cancer
    Date added:
    08/24/2022
    Date updated:
    04/25/2024
    Relationship end date:
    08/24/2022
Return to BTF Northwest Women’s Cancer Conference